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Abstract: Many risk factors for coronary
heart disease (CHD) have been reported to
date. Recently, it has been shown that
elevations in homocysteine (Hcy) levels may
contribute to the development of coronary
heart diseases. In this study, our aim was to
determine the relation of Hcy levels and other
risk factors in CHD.
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Serum Hcy, lipoprotein(a) [Lp(a)], C-reactive
protein (CRP), fibrinogen, cholesterol,
triglyceride, HDL and LDL levels were
measured in 51 male patients, diagnosed with
CHD with negative T elevations in
electrocardiograms, and in 20 healthy males.
Hcy was determined in serum samples with
Fluorescence Polarization Immunoassay
(FPIA) on Abbott IMx.
All the parameters were found to be
significantly higher (p<0.05) when compared

Introduction
Atherosclerosis, an important cause of mortality and
morbidity, is a chronic inflammatory process which
develops with the contribution of some risk factors. The
atherosclerosis of coronary arteries is the cause of CHD.
While age, sex and family history are unchangeable risk
factors, hypercholesterolemia, hypertriglyceridemia,
decreased HDL, hypercoagulable states, hypertension,
diabetes, smoking, sedentary life style, obesity and
personality are classic changeable risk factors in the
pathogenesis of atherosclerosis (1).
It was first shown in 1969 that elevated levels of Hcy
are associated with the development of atherosclerosis
(2). Hcy is a sulfur-containing amino acid derived from
the metabolism of methionine. Hcy seems to promote
atherosclerosis by a variety of mechanisms. Experimental
studies suggest that Hcy is probably the first agent that
interferes with endothelial function, and foam cell
generation comes as a later stage in the development of
atherosclerosis (3).

with those of the control group. The mean
Hcy levels in patients and control subjects
were
12.18±0.65µmol/L
and
3.73±0.43µmol/L respectively. It was found
that Hcy levels did not correlate with CRP,
fibrinogen or Lp(a) (p>0.05), while CRP was
well correlated with fibrinogen and Lp(a), and
Lp(a) was well correlated with fibrinogen
(p<0.05).
High levels of Hcy are associated with CHD
independent of other coronary risk factors.
Since high Hcy levels can easily be treated
with vitamin supplements, determining Hcy
concentrations on a routine basis may help to
reduce mortality and morbidity from
cardiovascular diseases.
Key Words: atherosclerosis, homocysteine,
fibrinogen, CRP, Lp(a)

Lp(a) is also identified as a risk factor in CHD. Many
reports have suggested that increased levels of Lp(a) are
correlated with CHD (4). The increased levels of CRP are
correlated with the presence and severity of
atherosclerosis and are strongly related to the occurrence
of cardiovascular complications (5).
In this study, our aim was to show Hcy levels and their
relation to the other risk factors in CHD.

Materials and Methods
Our study consisted of two groups of individuals. In
group 1, there were 51 non-smoking male patients,
mean age 54.76±1.66 years, admitted to the hospital
with acute myocardial infarction (AMI). The diagnosis of
AMI was based on typical chest pain, negative T elevations
and raised cardiac enzyme levels. Group 2 was the control
group and included 20 non-smoking males with a mean
age of 46.42±2.70 years. This group had no clinical
evidence of CHD.
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Fasting blood samples for Hcy measurements were
collected in 8mL Vacutainer tubes and kept on ice until
centrifugation. For serum preparation, blood was
centrifuged at 3000xg at 4ºC for 10 minutes without
delay and stored at –80ºC until Hcy analysis.
For Hcy measurements, FPIA was used on an
automatic analyzer (IMx, Abbott, Abbott Park, IL, USA).
Lp(a) levels were determined by agarose gel
electrophoresis (Sebia, Hyrys, France). CRP was
measured immunoturbidimetrically on an automatic
analyzer (Technicon RA-XT, Technicon Instruments,
Tarrytown, N.Y. USA). For fibrinogen measurements, we
used a coagulometric assay on an automatic analyzer
(Option 4, bioMerieux, France). Cholesterol, triglyceride,
HDL and LDL levels were determined using standard
laboratory methods on an automatic analyzer (Olympus
AU 5200, Olympus, Hamburg, Germany).
Statistical significance between the two groups was
assessed by independent samples t-test and the
correlation between tHcy, CRP, fibrinogen and Lp(a)
within the patient group was evaluated by Pearson
correlation coefficient. In evaluation of all the results, a p
value <0.05 was considered significant. For these
procedures, the Statistical Package for the Social Sciences
(SPSS, version 9.0, SPSS Inc., Chicago, IL, USA) was used
and the data are presented as mean±SEM.

Results
All the risk factors for CHD were significantly
different between the patients and control subjects in our
study (p<0.05). The mean values for cholesterol,
triglyceride, HDL, LDL, fibrinogen, Lp(a), CRP and Hcy
are shown in Table 1. The correlation coefficients for
CRP, Hcy, fibrinogen and Lp(a) are shown in Table 2.
The serum Hcy levels varied from 6.52 to 29.48
µmol/L (mean±SEM 12.18±0.65µmol/L) in 51 CHD
patients and from 1.12 to 8.3 µmol/L (mean±SEM
3.73±0.43µmol/L) in 20 control subjects (Table 1). Of
the 51 CHD patients, 8 (15.7% of total) had Hcy values
greater than 15µmol/L.
When we examined the correlation of CRP, Hcy,
fibrinogen and Lp(a) within the patient group, we found
that fibrinogen showed a strong correlation with
Lp(a)(r=0.796, p<0.05) and weak correlation with CRP
levels (r=0.465, p<0.05). Lp(a) was also weakly
correlated with CRP levels (r=0.412, p<0.05). We found
no correlation between Hcy and the other risk factors in
our study group.

Discussion
Since atherosclerosis represents the underlying
pathomechanism responsible for the majority of

Table 1.
Patients (n=51)

Hcy
Fibrinogen
Lp(a)
CRP
Cholesterol
Triglyceride
HDL
LDL

Control subjects (n=20)

Unit

Mean±SEM

Std. Dev.

Mean±SEM

Std. Dev.

p

µmol/L
mg/dL
%
mg/dL
mg/dL
mg/dL
mg/dL
mg/dL

12.18±0.65
372.13±12.09
1.76±0.19
4.70±0.34
187.07±9.11
152.80±13.21
38.19±1.09
126.68±8.18

4.65
86.39
1.36
2.45
65.06
94.38
7.83
58.47

3.73±0.43
233.40±6.36
0.01
0.19±0.03
160.45±6.04
76±5.61
45.70±2.17
100±5.33

1.96
28.45
0
0.15
27.05
25.11
9.71
23.86

<0.05
<0.05
<0.05
<0.05
<0.05
<0.05
<0.05
<0.05

Hcy
Hcy

Fibrinogen
r=0.122, p=0.395

Fibrinogen

r=0.122, p=0.395

Lp(a)

r=0.022, p=0.880

r=0.796, p=0.000

CRP

r=0.017, p=0.907

r=0.465, p=0.001

426

Lp(a)

CRP

r=0.022, p=0.880

r=0.017, p=0.907

r=0.796, p=0.000

r=0.465, p=0.001
r=0.412, p=0.003

r=0.412, p=0.003

Table 2.

Laboratory characteristics
patients and control subjects.

of

Correlation coefficients of Hcy,
Fibrinogen, Lp(a) and CRP.
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myocardial infarction cases, it is considered to be the
leading cause of death. Beside the established risk factors
for CHD, the search for possible additional ones such as
Lp(a), fibrinogen, CRP and Hcy is still in progress,
because classic risk factors alone do not explain the high
prevalence of this disease.
Studies in the last decade have indicated that
hyperhomocysteinemia is an independent risk factor in
the premature development of vascular diseases (6,7).
Initial observations linking Hcy to vascular diseases were
made by McCully more than 25 years ago in patients with
homocystinuria, in whom total plasma Hcy can be as
much as 50 times that found in normal subjects.
However, recent studies have demonstrated that even
mildly increased plasma Hcy can be a significant risk
factor (8).
There are many prospective and retrospective studies
about the association between hyperhomocysteinemia
and CHD that show parallelism with our results. Stampfer
et al. (9), Arnesen et al. (10), Wald et al. (11) and Nygard
et al. (12) reported that Hcy concentrations were higher
in patient groups with CHD than in control subjects. The
mean concentration of Hcy varies between studies.
Stampfer et al. studied 542 male participants and found
Hcy mean concentrations of 11.1±4 versus
10.5±2.8µmol/L. Arnesen et al. performed a study in
601 participants and they also found Hcy concentrations
higher in the patients: 21.7±4.7 versus 11.3±3.7µmol/L.
In Wald et al.’s study, there were 229 patients who died
of CHD. Their mean Hcy concentration was 13.1 versus
11.8µmol/L. Nygard et al.’s study included 587 patients
and they also found higher Hcy concentrations in the
patients. In our study, which included 51 patients that
had survived myocardial infarction and 20 control
subjects, mean Hcy concentrations were also higher than
in the control subjects (12.18±0.65 versus
3.73±0.43µmol/L). The concentration of Hcy at which
the risk begins to increase is not clear but all results show
a strong association between elevated Hcy levels and
CHD.
As there is a strong relation between cigarette
smoking and Hcy levels, our study group consisted of
non-smokers in order to eliminate the effect of smoking
on tHcy levels. Multivitamin tablet usage is quite common
in Turkey. In addition, fruits and vegetables, which are
important sources of folic acid and pyridoxine, are
produced and consumed in large quantities in Turkey.

There is a high intake of foods of plant origin rather than
animal protein consumption. Those facts may explain the
lower tHcy mean levels in our study when compared to
some other reports.
There was no correlation between Hcy and fibrinogen
concentrations in our study (r=0.122, p>0.05). Malinow
et al. (13) found a positive correlation between Hcy and
fibrinogen. They assumed that high concentrations of Hcy
may lead to the release of fibrinogen into plasma. As Hcy
inhibits thrombomodulin and protein C activation, Hcy
may lead to increased production of thrombin and
fibrinogen and this may favor thrombosis. Increased
fibrinogen levels are associated with acute coronary
syndromes (5). Fibrinogen levels were significantly higher
than those observed in the control group in our study
(p<0.05). Fibrinogen had a weak correlation with CRP
(r=0.465, p<0.05) and a strong correlation with Lp(a)
(r=0.796, p<0.05).
The strong association between CRP levels and the
risk of CHD has been shown in several studies (5,14).
There is a positive association between CRP concentration
and CHD risk. The increased levels of CRP and fibrinogen,
both of them acute phase reactants, supports the idea
that the inflammatory process has a role in these cases.
The secretion of CRP is induced by cytokines, especially
interleukin-6 (IL-6), and it has been suggested that IL-6
is the major mediator involved in the acute phase
inflammation in AMI (15). CRP levels were significantly
higher in our patient group than in the healthy control
group (p<0.05). March et al. (16), Abdelmouttaleb et al.
(5) and Delanghe et al. (17) found increased CRP
concentrations in patients with AMI. Our results
(4.70±0.34 versus 0.19±0.03mg/dL) confirm the
existing relation between CRP levels and the presence of
CHD. It was also proposed that CRP might play an
atherogenic role through an interaction with LDL, but we
found no correlation between CRP and LDL levels in our
study group (r=0.03,p>0.05). This finding may suggest
that CRP does not play a role as a promoter of chronic
atherosclerosis.
Lp(a) is increased in patients with cardiovascular and
cerebrovascular diseases. In 1963, Kare Berg first
described Lp(a) as a lipoprotein antigen that was more
prevalent in the plasma of myocardial infarction survivors
(18). In this study, Lp(a) levels were higher when
compared with the control group (p<0.05). Lp(a) showed
a strong correlation with fibrinogen (r=0.796, p<0.05)
427

Homocysteine Levels and Other Risk Factors in Coronary Heart Disease

and a weak correlation with CRP levels (r=0.412,
p<0.05). However, not all prospective studies have
confirmed a positive relationship between Lp(a) and
cardiovascular events. Some, such as the Lipid Research
Clinic Study and the Gottingen Risk Incidence and
Prevalence Study, have shown a positive relationship
between Lp(a) and CAD, which is in accordance with our
results. However, among others, the Helsinki Heart
Study and the Physicians Heart Study have failed to show
a relationship between plasma Lp(a) and CAD (19). The
explanation of conflicting results may be due to the
condition of the samples, the methodology used for
assaying Lp(a), apo(a) isoform distribution, sample size
and duration of follow up. We used agarose gel
electrophoresis for the Lp(a) assay. This method has
limited value because the minimal level of detection is

0.15-0.20g/L and this method does not give the exact
Lp(a) levels. If we had used another method for Lp(a)
determination, we could have obtained higher values in
both groups but we do not think it would have made a
great difference to the statistics.
Since Hcy is an independent risk factor in CHD,
playing a significant role in the development of
atherosclerosis, plasma Hcy concentrations should be
determined, especially in patients who do not have other
classic risk factors. This study does not show a causal
relation between tHcy and mortality, but our results, like
other ones, may suggest that determining Hcy
concentrations on a routine basis may help to reduce
mortality and morbidity from cardiovascular diseases
since Hcy has been described as a common and easily
reversible risk factor for occlusive atherosclerosis.
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